Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

The genetic testing company 23andMe is poised to be sold to a nonprofit run by the company's former chief executive Anne Wojcicki.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a non-profit led by the company’s co-founder and former CEO Anne Wojcicki proposed a better offer to acquire the bankrupt DNA testing company.